• Home
  • Abzena
  • Improved Design & Delivery of ADCs & AOCs with ThioBridge® Site-Specific Conjugation

Improved Design & Delivery of ADCs & AOCs with ThioBridge® Site-Specific Conjugation

Improved Design & Delivery of ADCs & AOCs with ThioBridge® Site-Specific Conjugation
Product Description

Improve your ADC & AOC design and delivery with our ThioBridge® conjugation platform technology. Abzena's site-specific conjugation technology solution by provides a more uniform DAR & OAR profiles, stable linker attachment, and improved pharmacokinetic properties. ThioBridge® is important for the advancement of ADCs & AOCs. ThioBridge® provides several benefits for bioconjugate development as the technology addresses issues commonly associated with traditional bioconjugation technologies by: -Creating a very stable and uniform DAR & OAR composition -Improving manufacturing efficiency through a high-yielding ADC & AOC platform with up to 80% single DAR species -Exhibiting a high degree of stability in serum and being less prone to losing its payload in the body before it gets to its target -Allowing for an extensive range of linker designs to optimize the stability, loading and function of the payload -Providing versatility in the range of different payloads with different functions that can be attached to antibodies

Read more Show less

Abzena

  • Country/Region:
    United Kingdom
  • Founded:
    2001
  • On CPHI since:
    2025
  • Certificates:
    3
  • Employees:
    250 - 499
Company types
CMO/CDMO
Contract Research Organisation (CRO)
Pharmaceutical company
Primary activities
Contract Manufacturer
View company profile

Abzena

  • Country/Region:
    United Kingdom
  • Founded:
    2001
  • On CPHI since:
    2025
  • Certificates:
    3
  • Employees:
    250 - 499
Company types
CMO/CDMO
Contract Research Organisation (CRO)
Pharmaceutical company
Primary activities
Contract Manufacturer
View company profile

More Products from Abzena (4)

  • De-Risk Your Complex Biologic with Developability & Manufacturability Assessments

    Product De-Risk Your Complex Biologic with Developability & Manufacturability Assessments

    Abzena’s integrated approach to developability assessment ensures that your biologic or bioconjugate is not only viable but optimized for success. By continually refining our selection criteria and asking the right questions early, we de-risk projects and move closer to developing ideal drugs. Our stage-a...
  • Fully Integrated Development & Manufacturing Services for ADCs, AOCs, & RDCs

    Product Fully Integrated Development & Manufacturing Services for ADCs, AOCs, & RDCs

    Move your bioconjugate to patients faster with one fully integrated partner across linker-payload design & synthesis, highly potent API (HPAPI) development & manufacturing, & advanced bioconjugation services. With over 25 years of experience, 3,000+ conjugates developed, and 1,400+ linker-payloads desig...
  • GMP-Ready Mammalian Cell Line Development

    Product GMP-Ready Mammalian Cell Line Development

    GMP-ready, mammalian cell line development. Achieve stable pools in 3 weeks and accelerate from DNA to RCB in just 10 weeks & GMP in 6 months with up to 10g/L in high-performing titers. Abzena offers fully integrated stable pools to GMP manufacturing solutions with AbZelectPRO™, which is engineered for s...
  • Smarter Immunogenicity Testing with EpiScreen®2.0

    Product Smarter Immunogenicity Testing with EpiScreen®2.0

    Avoid issues later in the drug development process with smarter immunogenicity testing that improves candidate selection, reduces risk, and supports confident development decisions. Our enhanced bioassay platform EpiScreen® 2.0, is a comprehensive suite of assays that predict and evaluate potential risks ...